유산균 강화 막걸리의 유통과정 중 품질 특성

주현목,신태선,김진만 한국생물공학회 2022 KSBB Journal Vol.37 No.4

Makgeolli, one of Korean alcoholic beverages, have been increased market size since 2017 with the permission of online purchases. Several functional makgeolli by the addition of functional substances such as lactic acid from lactic acid bacteria(LAB) attracted the attention of consumers. We therefore studied the functional makgeolli in circulation which have been added both LAB as a probiotics and galactooligosacchride(GOS) as a prebiotics. Out of several combinations of LAB, mixture(S3) of Lactobacillus sakei(probiotics) and Lactobacillus sakei(parabiotics) added the GOS was shown the highest in the total bacterial cells. The GOS represented to the extent of positive effect for the growth and survival of LAB. The makgeolli with a high amount of total acid and lactic acid content improved quality due to the increase of sourness. Also, lactic acid increase from GOS addition induced proportionally antioxidative effect and received good reviews in the sensory evaluation without any deterioration of quality. These results indicated that the addition of LAB to makgeolli in circulation evaluated both the taste quality and functionality.

체중조절 방법에 관한 전국민 설문조사

주현목,권기한 한국식품영양과학회 2014 한국식품영양과학회 학술대회발표집 Vol.2014 No.10

난소의 악성 생식세포 종양 : 42예의 임상 병리학적 고찰 A Clinical and Pathological Study of 42 Cases

남주현,김용만,김소라,김종혁,목정은,나준희,전대준,김영탁 대한부인종양 콜포스코피학회 1998 Journal of Gynecologic Oncology Vol.9 No.3

From July, 1989 to June, 1998 forty-two patients with malignant germ cell tumors of the ovary treated in the department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center, were identified. Demographic characteristics, symptoms, signs, stage, tumor grade, mode of therapy and results of follow-up of those patients were reviewed retrospectively. The patients with malignant germ cell tumor constituted 11.1% of all ovarian malignancies and 5.6% of all ovarian germ cell tumors ecountered during this period. The most common histologic subtype was dysgerminoma (26.2%) followed by endodermal sinus tumor (23.8%) and immature teratoma (19.0%). The age of the patients ranged from 8 to 64 years (mean ±S.D.; 26.0 ±12.9) and the mean parity was 0.8 (±1.6). The most frequent initial symptoms were adbominal pain (33.3%) or abdominal distension (31.0%). Most had stage Ⅰ(25 cases, 59.9%) or Ⅱ(6 cases, 14.3%) diseases. Elevated level of serum α-FP was observed in all cases of endodermal sinus tumor and nal cell carcinoma, CA 125 was elevated in 63.9% of all malignant germ cell tumors. Thirty-one patients (73.8%) were treated by surgery and chemotherapy and 10 patients (23.8%) by surgery only. The major chemotherapeutic regimens were BEP (bleomycin +etoposide +cisplatin) and VAC (vincristine +actinomycin-D +cytoxan). The mean follow-up duration was 24.6 (±23.5) months and 2-year survival rate was 88.6% (±0.6).

포스타 : 종양학 ; 상피성 난소암에서 p53 변이에 관한 분자 유전학적 연구

남주현,송규영,조성원,김종혁,김용만,목정은 대한산부인과학회 1995 대한산부인과학회 학술대회 Vol.76 No.-

일반연제 발표 : 부인종양학 1 ; 국소적으로 진행된 자궁경부암에서 항암-방사선 동시치료의 효용성

목정은,남주현,손우석,김용만,김영탁,김종훈,장혜숙 대한산부인과학회 1996 대한산부인과학회 학술대회 Vol.78 No.-

제 77 차 춘계학술대회 : 논문초록 ( 부인과학 ) ; 상피성 난소암의 예후인자로서 혈청 CA 125 치 적용방법의 비교연구

남주현,김종혁,김용만,김영탁,목정은 대한산부인과학회 1996 춘계학술대회 Vol.- No.-

자궁내막증 치료에 있어서 GnRH agonist (Nafarelin Acetate) 의 효용성

목정은,이주학,고준성,남주현,정동근,전대준 대한산부인과학회 1994 Obstetrics & Gynecology Science Vol.37 No.10

자궁내막증 치료에 있어 GnRH agonist의 효용성을 알아보기 위하여 15명의 자궁내막증 환자를 대상으로 하여 nafarelin을 6개월간 비강내 분무투여 하여 다음과 같은 결과를 얻었다. 1. 혈중 E₂농도는 치료기간중에 유의한 감소를 보였으며, 혈중 CA-125농도도 치료시작전에 비해 치료시작후 의미있는 감소를 보였다. 2. 15명의 환자 모두에서 치료후 endometriosis score의 유의한 감소가 있었다. 3. 15명의 환자 모두에서 치료전의 증상이 치료기간 중에 증상의 소실 또는 호전을 보였다. 4. 부작용으로는 안면홍조, 질 건조감, 두통, 성교통, 유방크기의 감소, 불면증, 성욕감퇴, 근육통, 관절통, 체중증가, 우울증 등이 있었으나, 부작용으로 치료를 중단한 에는 없었다. 이상의 결과로 볼때 자궁내막증 환자에 있어 GnRH agonist(nafarelin)의 투여는 효과적이며 안전한 치료방법으로 사료된다. To evaluate the efficacy and safety of nafarelin for the treatment of endometriosis, twenty women with laparoscopically proven endometriosis were recruited to the study. The patient were treated with intranasal nafarelin, 400 micro g/day(100 micro twice a day) for 6 months. Efficacy assessments were based on preadmission and end-of treatment laparoscopic scores and subjective symptom scores at admission and end-of treatment. Safety was evaluated by adverse events. We observed following results. 1. Serum estradiol levels and serum CA-125 levels significantly fell during the treatment. 2. The endometriosis scores significantly decreased after treatment. 3. Symptoms of endometriosis significantly improved during treatment. 4. There was none of patients interrupted during treatment due to adverse effects. These data suggest that intranasal GnRH agonist, nafarelin is a effective and convenient approach to the medical treatment of endometriosis.

상피성 난소암의 예후인자로서 혈청 CA 125치 적용방법의 비교연구

남주현,김종혁,김용만,김영탁,목정은 대한산부인과학회 1996 대한산부인과학회 학술대회 Vol.77 No.-

국소적으로 진행된 자궁경부암의 방사선치료와 복합 항암화학요법의 동시치료 결과

강원철(One Chul Kang),최은경(Eun Kyung Choi),정원규(Weon Kuu Chung),김종훈(Jong Hoon Kim),장혜숙(Hyesook Chang),김용만(Yong Man Kim),김영탁(Young Tak Kim),남주현(Joo Hyun Nam),목정은(Jung-Eun Mok),이무송(Moo-Song Lee) 대한방사선종양학회 1998 Radiation Oncology Journal Vol.16 No.3

목 적 : 국소적으로 진행된 자궁경부암환자에서 방사선 치료와 5-FU, CDDP 복합항암요법의 동시 치료에 의한 종양관해율, 치료부작용, 예후인자, 실패양상과 생존율을 분석하기 위하여 전향적 제 2상연구를 시행하였다. 대상 및 방법 : 울산대학교 서울중앙병원 방사선종양학과와 산부인과에서 1992년 5월부터 1997년 1월까지 FIGO병기 IIB, III, IVA의 국소적으로 진행된 자궁경부암으로 진단받고 치료한 환자 73명중 방사선치료와 동시에 2회의 FP 항암요법을 시행한 68명을 대상으로 분석을 시행하였다. FIGO병기에 의한 분포는 IIB 46명, IIIA 2명, IIIB 15명, IVA 5명이었고, 이들의 연령분포는 31세에서 77세까지로 중앙값 58세이었다. 방사선치료시 외부조사는 전골반부에 4,140-5,040 cGy를 시행후 192Ir 고선량 근접치료기로 주 3회씩 6-7회의 강내조사를 시행하며 동시에 B점추가조사를 시행하여 A점에 7,500-8,000 cGy, B점에 6,000-6,500 cGy가 되도록 조사하였다. FP (5-FU;1,000mg/m2/24 hours, 4 days+CDDP; 20mg/m2/3 hours, 3 days) 항암화학요법은 방사선치료 시작 제 1일과 제 29일에 각각 4일간 투여하도록 하였다. 치료효과는 치료종료시점과 치료후 1개월, 3개월에 시행한 부인과 검사와 MRI로 판정하였다. 결 과 : 전체 환자의 추적기간은 4개월에서 68개월 (중앙값 24개월)이었다. 생존율을 분석한 환자 64명의 5년생존율 및 무병생존율은 각각 52%와 64%였으며, FIGO병기 IIB인 환자의 5년생존율과 무병생존율은 각각 58%, 71%이었고, FIGO병기 III와 IVA인 환자는 각각 36%, 46%이었다. 재발양상은 전체 재발율이 27.9% (19/68)로, 국소재발이 5.9% (4/68), 원격전이가 10.3%(7/68), 국소재발과 원격전이가 같이 있는 경우가 11.8% (8/68)로 나타났다. 치료종료 한달 후 치료 효과를 판정할 수 있었던 64명중 78% (50/64)가 완전관해를 보였다. 예후인자는 단변량분석시 5년생존율에 FIGO병기, 치료반응율, 골반내와 대동맥주위 림프절 전이유무가 통계적으로 의미 있었고, 다변량분석시 치료반응율과 치료중 혈색소 농도가 통계적으로 의의있게 나타났다. 치료에 따른 독성은 10%내외로 치료후 대부분 자연 회복되었으나, 2차 항암약물투여중 폐부종이 발생한 1명과 치료종료후 8개월에 만성합병증인 장천공이 발생한 1명은 치료에 따른 부작용으로 사망하였다. 결 론 : 국소적으로 진행된 자궁경부암에 대한 방사선치료와 복합항암요법의 동시치료는 수용 가능한 독성을 보였고, 진행된 경우 생존율의 향상을 관찰할 수 있었다. 좀 더 장기적인 추적관찰 후 여러 예후인자들을 고려하여 초기 치료반응율을 높이는 치료방법의 선택이 필요하리라 생각되며, 동시 방사선-항암화학요법의 종양관해율과 생존율의 차이를 알아보기 위한 제 3상 무작위 연구가 필요한 것으로 생각된다. Purpose : Prospective, single arm, Phase I/II clinical trial was performed to assess the efficacy and toxicity of the concurrent chemotherapy and definitive radiotherapy (RT) in patients with previously untreated locally advanced carcinoma of the uterine cervix. Methods and Materials : From May 1992 to January 1997, a total of 73 patients with advanced cervical carcinoma were entered on the protocol but 5 patients were excluded in analysis because of patients' refusal of treatment. Their ages ranged from 31 to 77 years, median 58 years. The International Federation of Gynecology and Obstetrics (FIGO) stage distribution was as follows: IIB 46, IIIA 2, IIIB 15 and IVA 5. RT consisted of external beam irradiation to 4,140-5,040 cGy/23-28 fractions plus high dose rate intracavitary treatments to deliver a dose of 30-35 Gy to point A in 6-7 fractions. During the intracavitary treatments parametrial boost was delivered for point B dose of 60 Gy in stage IIB and 65 Gy in stage IIIB. Two cycles of concurrent 5-fluorouracil and cisplatin (FP) chemotherapy (5-fluorouracil 1,000 mg/m2/day continuous infusion for 4 days, day 1-4, 29-32 and cisplatin 20 mg/m2/day intravenous bolus for 3 days, day 1-3, 29-31) administered starting on day 1 of RT. Results : The median follow -up was 24 months (range 4-68+). Sixty-four patients were evaluable for survival rate in this protocol; The 5-year actuarial and disease-free survival rate were 52% and 64%, respectively. The 5-year actuarial survival for stage IIB and III+IVA patients were 58% and 36%, respectively. The 5-year disease-free survival rate for stage IIB and III+IVA patients were 71% and 46%, respectively. Of the 68 patients evaluated for patterns of failure, overall recurrence rate was 27.9% (19/68): local failure in 5.9% (4/68), distant metastasis in 10.3% (7/68) and both in 11.8% (8/68). Of the 64 patients evaluated for response at one month after the completion of treatment, the complete response rate was 78% (50/64). Concurrent chemoradiation appear to be a well-tolerated regimen but there were two treatment-related deaths. Conclusion : Concurrent chemotherapy of FP with high-dose definitive RT in locally advanced carcinoma of the uterine cervix is feasible and effective with acceptable toxicities. This chemoradiation regimen may offer a modest survival benefit for advanced stage. Further follow -up of these patients will evaluate the impact of this regimen on the long-term local control and their survival.

원발성 난소 명세포암의 임상병리학적 연구

목정은(Jung Eun Mok),정지윤(Ji Yoon Jung),나준희(Jun Hee Na),김종혁(Jong Hyeok Kim),김봉희(Bong Hee Kim),허주령(Joor Rung Huh),김용만(Yong Man Kim),김영탁(Young Tak Kim),남주현(Joo Hyun Nam) 대한산부인과학회 1998 Obstetrics & Gynecology Science Vol.41 No.12

N/A Clear cell carcinoma of the ovary is a clinicopathologic entity with distinct morphologic characteristics and known to be associated with poor prognosis irrespective of stage and prognostic benefits of chemotherapy have not been evidently demonstrated. This represents 2-3.6% of all ovarian malignancies. From October, 1991 to January, 1998, nine patients with primary clear cell carcinoma of the ovary treated in the deptartment of Gynecology and Obstetrics, University of Ulsan, Asan Medical Center were identified, and clinical and histologic review(including architectural pattern, mitotic activity, nuclear grading) was performed retrospectively. The age of the patients ranged from 30 to 67 year(mean+S.D.; 46.0+11.8) and the mean parity was 1.2 (+1.3). Five(55.6%) of nine patients had elevated level of CA 125. The size of the tumors varied from 3 cm to 20 cm with the mean maximal diameter of 12.1 (+6.3) cm. The FIGO stages of the patients were IC(6 cases, 66.7%), IIC (2 cases, 22.2%) and IV(1 case, 11.1%). All patients except one were treated by total abdominal hysterectomy and bilateral salpingoophorectomy with or without omentectomy and pelvic lymph node dissection. All except two were received postoperative chemotherapy with regimens such as CEC (cyclophosphamide + epirubicin + carboplatin), TC(taxol + carboplatin), CC(cyclophosphamide + carboplatin) or CAP (cyclophosphamide + adriamycin + cisplatin). The mean follow-up duration was 14.6 (+ 8.6) months and 8 patients were free of disease and one patient with stage IV disease died of disease during postoperative chemotherapy(4 months after surgery).